Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

2.

Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.

Kirouac DC, Lahdenranta J, Du J, Yarar D, Onsum MD, Nielsen UB, McDonagh CF.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00019. doi: 10.1002/psp4.19. Epub 2015 Mar 4.

3.

Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.

Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, MacBeath G, Hendriks BS.

Am J Pathol. 2013 Nov;183(5):1446-1460. doi: 10.1016/j.ajpath.2013.07.015. Epub 2013 Sep 11.

PMID:
24035511
4.

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.

Sci Signal. 2013 Aug 13;6(288):ra68. doi: 10.1126/scisignal.2004008. Erratum in: Sci Signal. 2014 Sep 30;7(345):er5.

PMID:
23943608
5.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16.

6.

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS.

Blood. 2009 Apr 30;113(18):4352-61. doi: 10.1182/blood-2008-09-179143. Epub 2009 Jan 15.

7.

Preclinical characterization of SGN-70, a humanized antibody directed against CD70.

McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL.

Clin Cancer Res. 2008 Dec 1;14(23):7763-72. doi: 10.1158/1078-0432.CCR-08-0493.

8.

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.

McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ.

Mol Cancer Ther. 2008 Sep;7(9):2913-23. doi: 10.1158/1535-7163.MCT-08-0295.

9.

Anti-CD30 diabody-drug conjugates with potent antitumor activity.

Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, Lyon R, Alley SC, Okeley NM, Zhang X, Thompson MC, Stone I, Gerber HP, Carter PJ.

Mol Cancer Ther. 2008 Aug;7(8):2486-97. doi: 10.1158/1535-7163.MCT-08-0388.

10.

Antibody targeting of B-cell maturation antigen on malignant plasma cells.

Ryan MC, Hering M, Peckham D, McDonagh CF, Brown L, Kim KM, Meyer DL, Zabinski RF, Grewal IS, Carter PJ.

Mol Cancer Ther. 2007 Nov;6(11):3009-18.

11.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL.

Blood. 2007 Feb 1;109(3):1185-92. Epub 2006 Oct 12.

12.

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, Carter P.

Protein Eng Des Sel. 2006 Jul;19(7):299-307. Epub 2006 Apr 27.

PMID:
16644914
13.

Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.

McDonagh CF, Beam KS, Wu GJ, Chen JH, Chace DF, Senter PD, Francisco JA.

Bioconjug Chem. 2003 Sep-Oct;14(5):860-9.

PMID:
13129388

Supplemental Content

Loading ...
Support Center